Abstracts

INTRAMUSCULAR SOTROVIMAB IS NONINFERIOR TO INTRAVENOUS SOTROVIMAB FOR COVID-19

Sotrovimab is a pan-sarbecovirus neutralizing monoclonal antibody shown to be safe and effective for the treatment of early COVID-19 in high-risk patients and retains activity against variants of concern, including delta and omicron. To facilitate wider access to sotrovimab, it was formulated to allow for either intramuscular (IM) or intravenous (IV) administration. COMET-TAIL (NCT04913675) is…

EFFECT OF SEROSTATUS ON THE EFFICACY OF SOTROVIMAB IN PREVENTING COVID-19 PROGRESSION

Sotrovimab is a pan-sarbecovirus monoclonal antibody clinically evaluated for prevention of progression of COVID-19 in high-risk patients early in the course of infection. We investigated the rate of prevention of hospitalization or death by baseline anti-SARS-CoV-2 serostatus. COMET-ICE (NCT04545060) was a multicenter, double-blind, phase 3 trial in nonhospitalized adults with symptomatic COVID-19 and ?1 risk…

CAMOSTAT IS NOT EFFECTIVE FOR MILD-MODERATE COVID-19 IN A PHASE II TRIAL OF ACTIV-2

Camostat, a serine protease inhibitor, prevents activation of the SARS-CoV-2 spike protein and blocks SARS-CoV-2 infection in vitro. We studied the safety and antiviral and clinical efficacy of orally administered camostat in non-hospitalized adults with mild-moderate COVID-19. ACTIV-2/A5401 is a platform trial to evaluate therapies for non-hospitalized adults with mild-moderate COVID-19. In a phase 2…